scispace - formally typeset
K

Klaus Bacher

Researcher at Ghent University

Publications -  95
Citations -  2148

Klaus Bacher is an academic researcher from Ghent University. The author has contributed to research in topics: Image quality & Radionuclide therapy. The author has an hindex of 27, co-authored 87 publications receiving 1903 citations.

Papers
More filters
Journal ArticleDOI

γ-H2AX Foci as a Biomarker for Patient X-Ray Exposure in Pediatric Cardiac Catheterization Are We Underestimating Radiation Risks?

TL;DR: &ggr;-H2AX foci as a biomarker for DNA damage indicate that radiation risk estimates according to the linear-no-threshold hypothesis are possibly underestimates, and great care should be taken to minimize and optimize patient radiation exposure.
Journal ArticleDOI

Dose reduction in patients undergoing chest imaging: digital amorphous silicon flat-panel detector radiography versus conventional film-screen radiography and phosphor-based computed radiography.

TL;DR: The introduction of digital flat-panel radiography systems based on amorphous silicon and cesium iodide is an important step forward in chest imaging that offers improved image quality combined with a significant reduction in the patient radiation dose.
Journal ArticleDOI

Cone beam computed tomography, a low-dose imaging technique in the postoperative assessment of cochlear implantation.

TL;DR: These preliminary results suggests that, for in vivo postoperative evaluation of cochlear implants, CBCT can provide at least the same information as conventional radiography, digital radiograph, and MSCT but in a more comfortable and a much more safer way.
Journal ArticleDOI

Optimised tracer-dependent dosage cards to obtain weight-independent effective doses.

TL;DR: Using the EANM factors for tracers belonging to clusters B and C results in significantly higher effective doses to children, and is suggested using three tracer-dependent dosage cards for which the correction factors have been calculated to obtain weight-independent effective doses.
Journal Article

188Re-HDD/Lipiodol Therapy for Hepatocellular Carcinoma: A Phase I Clinical Trial

TL;DR: After the intraarterial administration of 3.60 GBq (188)Re-HDD/lipiodol, a fast clearance of the activity appearing in the blood is observed and the predominant elimination is through urinary excretion and the tolerance as well as the preliminary response rates are encouraging.